Skip to content
Biotechnology

Bionic eye trial reveals substantial vision improvements over two and a half years

Centre for Eye Research Australia. Bionics Institute. Bionic Vision Technologies 4 mins read

Results of the first clinical trial of Australia’s ‘second generation’ bionic eye have demonstrated ‘substantial improvement’ in four participants’ functional vision, daily activities and quality of life over a period of more than two and a half years.

Detailed outcomes from the trial, led by the Centre for Eye Research Australia, Bionics Institute, University of Melbourne and Royal Victorian Eye and Ear Hospital, are published in Ophthalmology Science.

The findings add to interim results which showed that the second-generation bionic eye developed by Australian company Bionic Vision Technologies provided rapid improvements for four patients with blindness caused the genetic eye condition retinitis pigmentosa.

Retinitis pigmentosa is an inherited retinal disease which affects about two million people worldwide and is one of the leading causes of vision loss in working-age people.

The bionic eye comprises an electrode array, designed by the Bionics Institute and the Centre for Eye Research Australia, that is surgically implanted behind the eye. The electrode receives signals from a video camera mounted on glasses, which stimulate the patient’s retina.

Professor James Fallon, Head of Research at the Bionics Institute said: “The camera converts images into electrical pulses delivered by the electrode array that activate retinal cells and create flashes of light called phosphenes to help patients detect edges, shapes and movement.’’

 

The new study tracked the patients from the time they received the implant surgery in 2018 to 2021. Its findings demonstrate the device is stable and durable over the longer term– staying in place behind the retina without complication and still having 97 per cent of electrodes functioning 2.7 years after first implant.

Principal Investigator and vitreo-retinal surgeon Associate Professor Penny Allen said patients showed significant improvement in their navigation, mobility and ability to detect objects – in clinical tests, at home and in the community.

“The bionic eye enabled blind patients to locate doorways, avoid obstacles and find items on table-tops,’’ she said. “They reported greater confidence in navigation, were more likely to explore new environments and had reduced need for assistance when travelling to the local shops.’’

Associate Professor Allen said participants reported that the bionic eye supplemented long cane and guide dog use, provided safe navigation around people and obstacles, and allowed them to detect waypoints such as trees and lamp posts along navigational routes.“Patients were also able to locate their spouse in a café and detect people moving at a train station – things they could not do without using their bionic eye.’’

Bionic Vision Technologies’ team is continuing to refine the vision processing capabilities, usability, as well as the wearables of the bionic eye system.

Dr Ash Attia, CEO of Bionic Vision Technologies said: “ We are encouraged  by  the excellent results of the generation 2 Bionic eye trial. We are looking forward to finalise the development of the Generation 3 bionic eye and enter the worldwide pivotal trial and ultimately gain regulatory approval. Regulatory approval will allow us to make this important technology available to RP patients which will positively impact their lives” Dr Attia said.

Interviews: Associate Professor Penny Allen, Professor James Fallon and a bionic eye research project participant and Ash Attia from Bionic Vision Technologies are available for interview.

Video footage: Video footage of trial participants in action and phosphenes is available.

Read the study    https://doi.org/10.1016/j.xops.2024.100525

Petoe, Matthew A., et al. "A Second-Generation (44-Channel) Suprachoroidal Retinal Prosthesis: A Single-Arm Clinical Trial of Feasibility." Ophthalmology Science (2024): 100525.

Media contacts:

For Associate Professor Penny Allen and trial participants:  Janine Sim-Jones, Centre for Eye Research Australia,  jsimjones@cera.org.au, +61 420 886 511

For Professor James Fallon, Chief Technology Officer and Head of Research Operations, Breanna Smith, Bionics Institute , bsmith@bionicsinstitute.org, +61 499 399 510

For Bionic Vision Technologies  Dr Ash Attia,  Chief Executive Officer ash.attia@bionicvis.com, +61 419 691 229

About the Centre for Eye Research Australia  The Centre for Eye Research Australia (CERA) is an independent medical research institute based at the Royal Victorian Eye and Ear Hospital in Melbourne and affiliated with the University of Melbourne. An international leader in eye research, we’re deeply committed to conducting research with real-life impact. Our goal is to prevent vision loss and blindness and, ultimately, find cures to restore sight.

About the Bionics Institute  The Bionics Institute is an internationally recognised, independent medical research institute that solves medical challenges with technology. We lead the world in the research and development of innovative medical devices and therapies to transform the lives of people with hearing and vision impairment, autoimmune and chronic conditions, and conditions affecting the brain. For more information, go to: www.bionicsinstitute.org

Bionic Vision Technologies Bionic Vision Technologies Pty Ltd (BVT) is a privately owned ophthalmic research and development company dedicated to restoring functional vision to the visually impaired. The company is currently working on two main projects: an implantable bionic eye system for individuals severely affected by Retinitis pigmentosa, and a non-implantable device that helps blind users detect and navigate around objects using vibration. Both products have undergone clinical feasibility studies. The company is now seeking funding to complete further studies for regulatory approval and eventual commercialisation in global markets.


About us:

About the Centre for Eye Research Australia  The Centre for Eye Research Australia (CERA) is an independent medical research institute based at the Royal Victorian Eye and Ear Hospital in Melbourne and affiliated with the University of Melbourne. An international leader in eye research, we’re deeply committed to conducting research with real-life impact. Our goal is to prevent vision loss and blindness and, ultimately, find cures to restore sight.

About the Bionics Institute  The Bionics Institute is an internationally recognised, independent medical research institute that solves medical challenges with technology. We lead the world in the research and development of innovative medical devices and therapies to transform the lives of people with hearing and vision impairment, autoimmune and chronic conditions, and conditions affecting the brain. For more information, go to: www.bionicsinstitute.org

About Bionic Vision Technologies Bionic Vision Technologies Pty Ltd (BVT) is a privately owned ophthalmic research and development company dedicated to restoring functional vision to the visually impaired. The company is currently working on two main projects: an implantable bionic eye system for individuals severely affected by Retinitis pigmentosa, and a non-implantable device that helps blind users detect and navigate around objects using vibration. Both products have undergone clinical feasibility studies. The company is now seeking funding to complete further studies for regulatory approval and eventual commercialisation in global markets.


Contact details:

Janine Sim-Jones, Centre for Eye Research Australia,  jsimjones@cera.org.au, +61 420 886 511

Breanna Smith, Bionics Institute , bsmith@bionicsinstitute.org, +61 499 399 510

ash.attia@bionicvis.com, +61 419 691 229

 

 

More from this category

  • Biotechnology, Results Statistics
  • 31/05/2024
  • 07:54
The Lottery Corporation Ltd

Powerball Draw no. 1463

Official Results Powerball Draw no. 1463 Draw Date: Thursday, 30 May 2024 Drawn Numbers Winning Numbers 35 2 3 33 20 22 10 (drawn order) Powerball 9 Dividends Dividends Total Winners Total Prizes Payable Division 1 $0.00 0 $0.00 Division 2 $270,217.65 1 $270,217.65 Division 3 $9,598.45 35 $335,945.75 Division 4 $571.70 511 $292,138.70 Division 5 $192.00 1,141 $219,072.00 Division 6 $79.50 17,268 $1,372,806.00 Division 7 $49.50 21,547 $1,066,576.50 Division 8 $20.30 111,436 $2,262,150.80 Division 9 $11.90 326,742 $3,888,229.80 478,681 $9,707,137.20 Division 1 Jackpots to $12,000,000.00

  • Contains:
  • Biotechnology
  • 30/05/2024
  • 20:07
Moolec Science SA

Moolec Science Presents Third Quarter Fiscal Year 2024 Business Update

LUXEMBOURG / ACCESSWIRE / May 30, 2024 / Moolec Science SA (NASDAQ:MLEC) a science-based food ingredient company focused on producing animal proteins in plants through Molecular Farming technology, announced today its Business Update for the third quarter of Fiscal Year 2024 ended March 31, 2024.Moolec Science Logo The main highlights of Moolec's business update are as follows:Piggy Sooy™ Product | Soybean Platform: Moolec's patented soybean product received USDA-APHIS Regulatory Status Review approval in April 2024.Safflower Platform: GLASO™ planting campaign progressing as expected. Two US Patents granted for production of chymosin in safflower seeds (SPC2) extended exclusive technology protection until 2041.Financial…

  • Biotechnology
  • 28/05/2024
  • 20:07
The BioMed X Institute

BioMed X Institute and Boehringer Ingelheim Successfully Complete Schizophrenia Research Project

The research of BioMed X team EPD - Early Intervention in Psychiatric Diseases - has shed light on the molecular mechanisms underlying white matter deficits in schizophrenia.HEIDELBERG, GERMANY / ACCESSWIRE / May 28, 2024 / German independent research institute BioMed X announces the successful completion of its second neuroscience project in partnership with Boehringer Ingelheim in the field of psychiatric disorders. The data resulting from this project have been acquired by Boehringer Ingelheim, where this research will be continued, potentially paving the way for novel therapies. This research project was launched in 2020 at the BioMed X Institute in Heidelberg…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.